Biliary tract cancer articles from across Nature Portfolio

The application of fibroblast growth factor receptor (FGFR)−2 selective tyrosine kinase inhibitors (TKIs) in cholangiocarcinoma (CCA) with FGFR2 fusions has been reported to lead to mutations in the kinase domain of FGFR2.

Here, the authors report that non-selective TKI, lenvatinib may be an alternative in case of insurmountable side effects to specific FGFR inhibitors or to overcome and delay the development of resistance mediating FGFR2 mutations.

Cholangiocarcinoma can arise anywhere within the biliary tree and is classified by anatomical locations. Here, the authors utilised RNAseq from 438 CCA patients and propose a molecular classification system independent of location.